Paper41202502
Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure.
da Silva IP and 11 others. ESMO Open, 2025. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure. Papers, record 41202502. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41202502
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immune Checkpoint Inhibitors | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Retreatment | |
| Treatment Failure |
Source PubMed
References79
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37348035 | Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/37348035 | PubMed |
| 2 | 35832458 | Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study. | Transl Lung Cancer Res | 2022 | https://conductscience.org/library/papers/35832458 | PubMed |
| 3 | 38722641 | Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial. | JAMA Oncol | 2024 | https://conductscience.org/library/papers/38722641 | PubMed |
| 4 | 30231380 | Patterns of Response and Progression to Immunotherapy. | Am Soc Clin Oncol Educ Book | 2018 | https://conductscience.org/library/papers/30231380 | PubMed |
| 5 | 31050774 | Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. | JAMA Netw Open | 2019 | https://conductscience.org/library/papers/31050774 | PubMed |
| 6 | 36780608 | Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36780608 | PubMed |
| 7 | 32605892 | Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients. | Clin Lung Cancer | 2020 | https://conductscience.org/library/papers/32605892 | PubMed |
| 8 | 34986285 | Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. | N Engl J Med | 2022 | https://conductscience.org/library/papers/34986285 | PubMed |
| 9 | 34254534 | Outcomes after retreatment with MAPK inhibitors and immune checkpoint inhibitors in melanoma patients. | Future Oncol | 2021 | https://conductscience.org/library/papers/34254534 | PubMed |
| 10 | 37071838 | Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/37071838 | PubMed |
| 11 | 32078391 | Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/32078391 | PubMed |
| 12 | 33303685 | Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. | Science | 2021 | https://conductscience.org/library/papers/33303685 | PubMed |
| 13 | 33894335 | Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. | Ann Oncol | 2021 | https://conductscience.org/library/papers/33894335 | PubMed |
| 14 | 37852736 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/37852736 | PubMed |
| 15 | 35222642 | REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study. | J Oncol | 2022 | https://conductscience.org/library/papers/35222642 | PubMed |
| 16 | 33945288 | Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/33945288 | PubMed |
| 17 | 35867951 | Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/35867951 | PubMed |
| 18 | 28650338 | IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. | J Clin Invest | 2017 | https://conductscience.org/library/papers/28650338 | PubMed |
| 19 | 32681091 | Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. | Nat Commun | 2020 | https://conductscience.org/library/papers/32681091 | PubMed |
| 20 | 33857412 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/33857412 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42707037 | Cancer survivorship in malignant melanoma. | J Dtsch Dermatol Ges | 2026 | https://conductscience.org/library/papers/42707037 | PubMed |
| 42449707 | Rational Immune Checkpoint Inhibitor-Based Combination Immunotherapy in Cancer: Mechanistic Design, Biomarker Selection, and Implications for Oncology Pharmacy. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42449707 | PubMed |
| 42343297 | Therapeutic outcomes of PD-1 blockade-related regimens versus docetaxel in previously immunotherapy-treated advanced non-small cell lung cancer: a retrospective, exploratory study. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42343297 | PubMed |
| 42014741 | Microbiota-derived metabolites as modulators of cancer immunotherapy response. | Nat Commun | 2026 | https://conductscience.org/library/papers/42014741 | PubMed |
| 41963855 | Efficacy and safety of albumin-bound paclitaxel combined with anlotinib and immunotherapy in advanced non-small cell lung cancer with liver metastases: a retrospective study. | BMC Cancer | 2026 | https://conductscience.org/library/papers/41963855 | PubMed |
| 41898300 | Targeting T-Cells for Cancer Treatment: Current Clinical Strategies and Challenges. | Biomedicines | 2026 | https://conductscience.org/library/papers/41898300 | PubMed |
| 41883115 | Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard-of-Care and Emerging Therapeutic Strategies. | J Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/41883115 | PubMed |
| 41816339 | Evolving epidemiology and improving safety of rechallenge in immune checkpoint inhibitor-associated acute kidney injury: an updated meta-analysis. | Front Immunol | 2026 | https://conductscience.org/library/papers/41816339 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41202502
GET https://conductscience.org/api/papers/v1/41202502/references?page=2